
In a large retrospective study from 2020–2022, most COVID-19 treatments showed no clear benefit in real-life settings. Outpatient corticosteroid use increased hospitalizations. Among ICU patients, corticosteroids lowered intrahospital mortality (OR: 0.73). Other drugs, including remdesivir and tocilizumab, were associated with increased ICU admissions and longer stays. These findings underscore the need to reevaluate treatment strategies outside of clinical trials.
Like
Save
Share